8.2 Pediatric Heart Failure & Cardiomyopathies

8.2 Pediatric Heart Failure & Cardiomyopathies

Heart failure (HF) in pediatric patients is a clinical and pathophysiological syndrome characterized by the inability of the heart to deliver an adequate supply of oxygenated blood to metabolizing tissues, or the ability to do so only at abnormally elevated ventricular filling pressures. Unlike adult heart failure, which is predominantly driven by ischemic coronary artery disease, chronic hypertension, and age-related degenerative changes, pediatric heart failure arises from a heterogeneous spectrum of congenital structural heart defects, primary cardiomyopathies, myocarditis, and systemic metabolic insults.

---

Developmental Myocardial Physiology & Pediatric Pathophysiology

The immature myocardium possesses unique ultrastructural and mechanical characteristics that limit its adaptive reserve during hemodynamic stress:

1. Myofibrillar Architecture: Immature neonatal myocytes contain only 30% organized contractile elements (myofibrils) and 70% non-contractile mass (nuclei, cytoplasm, mitochondria), compared to 60% contractile myofibrils in mature adult myocytes.
2. Reduced Ventricular Compliance: The neonatal heart has high stiffness and poor passive diastolic distensibility. Consequently, it operates near the peak of its Frank-Starling curve under resting conditions. Volume loading (preload expansion) yields minimal increase in stroke volume ($SV$) while rapidly driving ventricular end-diastolic pressures into pulmonary venous congestion.
3. Heart Rate Dependency: Because stroke volume is relatively fixed by low compliance and myofibrillar immaturity, cardiac output ($CO = HR \times SV$) is critically dependent on heart rate. Severe bradycardia causes immediate circulatory collapse, whereas sustained extreme tachycardia ($> 200\text{ bpm}$) curtails diastolic filling time and induces ischemia.
4. Excitation-Contraction Coupling: Immature myocytes have a rudimentary, disorganized sarcoplasmic reticulum (SR) and lack a well-developed transverse tubule ($T$-tubule) invagination network. Intracellular calcium recycling is inefficient. The neonatal heart relies heavily upon extracellular calcium influx via sarcolemmal $L$-type calcium channels for contraction. Acute systemic hypocalcemia rapidly causes profound electromechanical uncoupling and cardiogenic shock.

                Developmental Differences: Immature vs Adult Myocardium

┌───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
│ Ultrastructural Feature       │ Neonate / Infant              │ Older Child / Adult           │
├───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
│ Contractile Myofibril Fraction│ ~30% of cell volume           │ ~60% of cell volume           │
│ Ventricular Compliance        │ Stiff, non-compliant          │ Compliant, distensible        │
│ Frank-Starling Reserve        │ Minimal (flat curve)          │ Substantial reserve           │
│ Determinant of Cardiac Output │ Heart rate dependent          │ Stroke volume & heart rate    │
│ Sarcoplasmic Reticulum        │ Immature, rudimentary         │ Dense, highly organized       │
│ Calcium Source for Systole    │ Extracellular trans-sarcolemmal│ Intracellular SR stores (CICR)│
└───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘

---

Etiological Spectrum of Pediatric Heart Failure

1. Left-to-Right Congenital Shunts (Pulmonary Overcirculation)

In defects characterized by non-cyanotic left-to-right communications—such as large ventricular septal defects (VSD), patent ductus arteriosus (PDA), and complete atrioventricular septal defects (AVSD)—congestive heart failure does not manifest at birth. In utero and during the first week of life, high pulmonary vascular resistance matches systemic vascular resistance, limiting shunt volume. Between 2 and 8 weeks of life, physiological regression of the pulmonary arteriolar smooth muscle media occurs, precipitating a steep drop in PVR.

As PVR falls, systemic arterial blood preferentially diverts across the defect into the low-resistance pulmonary circulation. This produces massive pulmonary overcirculation ($Q_p:Q_s > 2:1\text{ to }3:1$) and left-sided chamber volume overload. Clinically, infants present between 1 and 2 months of age with:

• Feeding Intolerance: Poor feeding, prolonged feeding duration ($> 30\text{ minutes}$), and failure to finish bottles ("eating is the infant's stress test").
• Diaphoresis: Sympathetic hyperactivation causing profound head sweating during feeds.
• Tachypnea & Retractions: Intercostal retractions, grunting, and persistent crackles.
• Failure to Thrive: Caloric expenditure on the work of breathing exceeds intake, resulting in severe weight gain faltering (dropping across percentiles on growth charts).

2. Dilated Cardiomyopathy (DCM)

DCM represents the most common pediatric cardiomyopathy, characterized by left ventricular chamber dilation and impaired systolic function ($EF < 45%$, fractional shortening $< 25%$). Etiologies include:

• Viral Myocarditis: Enteroviruses (coxsackievirus B), adenovirus, parvovirus B19, human herpesvirus 6, and SARS-CoV-2. Acute autoimmune-mediated myocyte necrosis leads to acute decompensated shock or chronic dilated cardiomyopathy.
• Genetic & Familial: Mutations in sarcomeric genes (TTN, MYH7), cytoskeletal proteins (DMD dystrophin in Duchenne and Becker muscular dystrophy), and mitochondrial respiratory chain enzymes.
• Anthracycline Cardiotoxicity: Chemotherapeutic agents (doxorubicin, daunorubicin) induce dose-dependent, progressive free-radical myocardial damage. Lifetime cumulative doses $> 300\text{ mg/m}^2$ significantly amplify late cardiomyopathy risks.

3. Hypertrophic Cardiomyopathy (HCM)

Characterized by disproportionate myocardial hypertrophy, myofibrillar disarray, and diastolic dysfunction, often with left ventricular outflow tract (LVOT) obstruction. Causes include autosomal dominant sarcomeric mutations (MYH7, MYBPC3), Rasopathies (Noonan syndrome with PRKAG2 mutations), metabolic storage disorders (Pompe disease / glycogen storage disease type II), and infants of diabetic mothers (IDM). In IDM, fetal hyperinsulinism stimulates glycogen and fat deposition in the interventricular septum; this condition is self-limiting, typically resolving over 3 to 6 months post-delivery as maternal glucose exposure ceases.

---

Neurohormonal Maladaptation in Children

Similar to adults, pediatric cardiac dysfunction triggers compensatory neurohormonal cascades that become maladaptive:

• Sympathetic Nervous System (SNS): Baroreceptor uncoupling drives chronic elevations in circulating epinephrine and norepinephrine, producing sinus tachycardia, increased myocardial oxygen demand, peripheral vasoconstriction, and progressive down-regulation/desensitization of cardiac $\beta_1$-adrenergic receptors.
• Renin-Angiotensin-Aldosterone System (RAAS): Diminished renal perfusion pressure prompts juxtaglomerular renin release. Angiotensin II induces intense arteriolar vasoconstriction (increasing systemic afterload and impeding forward cardiac output) and stimulates cellular hypertrophy and apoptosis. Aldosterone drives sodium and water retention in the distal nephron, exacerbating pulmonary edema and myocardial interstitial fibrosis.
• Natriuretic Peptides: Ventricular wall stress triggers cardiac secretion of B-type Natriuretic Peptide (BNP) and its biologically inert fragment, N-terminal pro-B-type Natriuretic Peptide (NT-proBNP). These biomarkers are elevated in pediatric heart failure and assist in differentiating cardiac pulmonary overcirculation from primary viral bronchiolitis.

---

Comprehensive Pharmacotherapy of Pediatric Heart Failure

                 Pediatric Heart Failure Pharmacotherapy Roadmap

   [Congestion & Volume Overload]         [Afterload Reduction & Neurohormonal]
                 │                                         │
                 ▼                                         ▼
       ┌──────────────────┐                     ┌───────────────────────┐
       │    Diuretics     │                     │    RAAS Antagonists   │
       └─────────┬────────┘                     └──────────┬────────────┘
                 │                                         │
       • Furosemide (1-2 mg/kg/dose)              • Captopril (0.05-0.1 mg/kg/dose)
       • Chlorothiazide (10-20 mg/kg BID)         • Enalapril (0.1 mg/kg/day)
       • Spironolactone (1-3 mg/kg/day)           • Sacubitril/Valsartan (ARNI)
                 │                                         │
                 └────────────────────┬────────────────────┘
                                      │
                                      ▼
                        ┌───────────────────────────┐
                        │   Long-Term Remodeling    │
                        └─────────────┬─────────────┘
                                      │
                         • Carvedilol (0.05-0.1 mg/kg BID)
                         • Metoprolol Succinate
                         • Digoxin (0.5-0.9 ng/mL target)

Diuretic Management Pearls

• Loop Diuretics: Furosemide is the initial agent for relieving pulmonary congestion and peripheral edema. Chronic high-dose use in preterms and neonates induces hypercalciuria, precipitating renal medullary nephrocalcinosis and osteopenia. Renal ultrasounds should monitor chronic neonatal therapy.
• Sequential Nephron Blockade: When chronic loop diuretic therapy causes hypertrophy of the distal convoluted tubule and compensatory sodium reabsorption (diuretic resistance), adding oral chlorothiazide ($10\text{ to }20\text{ mg/kg/dose}$ BID) produces synergistic, potent natriuresis. Potassium wasting is amplified, mandating aggressive potassium chloride supplementation.
• Aldosterone Antagonism: Spironolactone provides mild kaliuresis-sparing diuresis while preventing aldosterone-induced myocardial fibrosis. It is standard in pediatric dilated cardiomyopathy.

ACE Inhibitors: Dosing & Clinical Rules

• Captopril as the Titration Benchmark: In neonates, young infants, and hospitalized children with tenuous hemodynamics, captopril is the ACE inhibitor of choice. Because of its rapid onset and short half-life (1 to 2 hours), any catastrophic hypotension or precipitous drop in glomerular filtration can be reversed rapidly by withholding the drug. In contrast, long-acting agents like enalaprilat or lisinopril have prolonged durations of action (24 to 36 hours) that can prolong renal failure.
• Laboratory Monitoring Thresholds: Obtain serum creatinine (SCr), blood urea nitrogen (BUN), and serum potassium at baseline and 1 to 2 weeks following initiation or dose escalation.
  • An acute SCr increase of up to 30% above baseline is acceptable and reflects hemodynamic efferent arteriolar vasodilation rather than structural tubular injury.
  • If SCr rises $> 30%$ or serum potassium exceeds $5.5\text{ mEq/L}$, reduce the dose, evaluate intravascular volume status, and reassess concomitant medications (NSAIDs, spironolactone).

Beta-Adrenergic Blockade Principles

• Initiation Criteria: Beta-blockers (carvedilol or metoprolol succinate) must be started only when the patient is clinically stable, compensated, and euvolemic. Initiating beta-blockade during acute decompensated shock unmasks acute left ventricular failure, worsening cardiogenic collapse.
• "Start Low, Go Slow": Begin carvedilol at $0.05\text{ to }0.1\text{ mg/kg/dose}$ twice daily. Double the dose no more frequently than every 2 weeks, monitoring heart rate, blood pressure, and clinical signs of worsening fluid retention. Target doses ($0.4\text{ to }0.5\text{ mg/kg/dose}$ BID) confer optimal anti-remodeling benefits.

Digoxin: Narrow Therapeutic Index & Pediatric Toxicity

Digoxin exerts positive inotropy by reversibly inhibiting the sarcolemmal $\text{Na}^+/\text{K}^+$-ATPase pump, elevating intracellular sodium, which in turn drives the $\text{Na}^+/\text{Ca}^{2+}$ exchanger to pump calcium into the cytosol. More importantly in heart failure, it exerts neurohormonal suppression, reducing sympathetic outflow and enhancing parasympathetic tone.

• Target Serum Concentration: In pediatric heart failure, the therapeutic serum concentration is strictly $0.5\text{ to }0.9\text{ ng/mL}$. Serum levels $> 1.0\text{ to }1.2\text{ ng/mL}$ do not confer additional hemodynamic benefit and dramatically increase the risk of lethal proarrhythmia and mortality.
• Sampling Timing: Serum levels must be drawn at steady state at least 6 to 8 hours post-dose (preferably immediately prior to the next scheduled dose as a trough) to avoid elevated concentrations during the tissue distribution phase.
• Potentiating Factors for Toxicity:
  • Hypokalemia ($K^+ < 3.5\text{ mEq/L}$): Extracellular potassium competes with digoxin for binding to the $\text{Na}^+/\text{K}^+$-ATPase pump. Hypokalemia leaves more binding sites available, markedly intensifying digoxin effect and precipitating fatal ventricular arrhythmias even when serum digoxin levels are "normal" (e.g., $0.8\text{ ng/mL}$).
  • Hypomagnesemia & Hypercalcemia: Augment intracellular calcium overload, triggering triggered activity and delayed afterdepolarizations.
  • Renal Impairment: Digoxin is 70% to 80% eliminated unchanged via glomerular filtration; declining GFR causes rapid drug accumulation.
• Clinical Signs of Toxicity: Gastrointestinal symptoms (nausea, non-bilious vomiting, anorexia, poor feeding in infants), neurological signs (lethargy, blurred or xanthopsic [yellow-green] vision), and cardiac arrhythmias (sinus bradycardia, PR prolongation, high-grade AV block, junctional escape rhythms, premature ventricular contractions, bidirectional ventricular tachycardia).
• Antidotal Reversal: Administer Digoxin Immune Fab (DigiFab) for life-threatening arrhythmias, marked hyperkalemia ($K^+ > 5.5\text{--}6.0\text{ mEq/L}$ in acute overdose), or ingestion of $> 0.3\text{ mg/kg}$ in children.

Sacubitril/Valsartan (Entresto) in Pediatric Patients

Sacubitril/valsartan is an Angiotensin Receptor-Neprilysin Inhibitor (ARNI). Sacubitril is a prodrug whose active metabolite (sacubitrilat) inhibits neprilysin, preventing the degradation of endogenous vasoactive peptides (atrial natriuretic peptide, BNP, bradykinin, adrenomedullin), promoting natriuresis, vasodilation, and antifibrotic signaling. Valsartan selectively blocks the angiotensin II type 1 ($AT_1$) receptor.

• FDA Indication: Approved for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older (supported by the global PANORAMA-HF clinical trial).
• Pediatric Formulations & Dosing: Administered as an extemporaneously compounded or commercially manufactured oral suspension for children weighing $< 40\text{ kg}$ (tiered weight-band dosing starting at $1.6\text{ mg/kg/dose}$ BID and titrating to $3.1\text{ mg/kg/dose}$ BID), or as tablets in older children $\ge 40\text{ kg}$ (starting at $24/26\text{ mg}$ or $49/51\text{ mg}$ BID, titrating to $97/103\text{ mg}$ BID).
• The Critical 36-Hour Washout Rule:

  [!CAUTION] When switching a pediatric patient from an ACE inhibitor (captopril, enalapril, lisinopril) to sacubitril/valsartan, a mandatory 36-hour washout period must elapse between the last dose of the ACE inhibitor and the first dose of sacubitril/valsartan. Both ACE and neprilysin degrade bradykinin. Simultaneous inhibition results in massive bradykinin accumulation, causing catastrophic, life-threatening angioedema of the airway and facial tissues. When switching from an ARB, a washout period is not required.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1: Never administer an ACE inhibitor or ARNI without verifying baseline serum creatinine and potassium, and never co-prescribe potassium-sparing diuretics without a defined electrolyte monitoring schedule.
• Exam Trap 2: Digoxin therapeutic levels in heart failure are $0.5\text{ to }0.9\text{ ng/mL}$, NOT the older adult antiarrhythmic target of $0.8\text{ to }2.0\text{ ng/mL}$. High-normal levels in infants receiving furosemide risk fatal arrhythmias.
• Board Rule: Large left-to-right shunts present with heart failure between 2 and 8 weeks of life, exactly matching the timeline of falling pulmonary vascular resistance. If a 3-day-old infant presents in shock, suspect ductal-dependent congenital heart disease or sepsis, not uncomplicated VSD pulmonary overcirculation.